Form 4: Inozyme Pharma Director Reinaldo Diaz Acquires 28,000 Stock Options

Director Reinaldo Diaz of Inozyme Pharma, Inc. was granted 28,000 stock options on June 18, 2024, according to a Form 4 filing with the SEC.

Summary

• Reinaldo Diaz, a director of Inozyme Pharma, Inc., filed a Form 4 with the SEC.
• The filing reports that Mr. Diaz was granted 28,000 stock options on June 18, 2024.
• The exercise price of the options is $4.40.
• The options vest 100% on June 18, 2025, or immediately prior to the first annual meeting of stockholders occurring after the grant date, if earlier.
• The options expire on June 17, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard SEC filing related to stock option grants, which is a common practice. There's no indication of positive or negative news about the company's performance.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and align management interests with shareholder value.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.

Key Dates